Novavax, Inc.
Novavax, Inc., a leading biotechnology company headquartered in the United States, focuses on the development of innovative vaccines to combat infectious diseases. Founded in 1987, Novavax has made significant strides in the vaccine industry, particularly with its proprietary nanoparticle technology, which enhances immune responses. The company is renowned for its COVID-19 vaccine candidate, NVX-CoV2373, which has demonstrated promising efficacy in clinical trials. Novavax's commitment to advancing vaccine development has positioned it as a key player in the global health landscape, particularly in the fight against emerging infectious diseases. With a strong emphasis on research and development, Novavax continues to expand its portfolio, aiming to address unmet medical needs worldwide.
DitchCarbon Score
How does Novavax, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novavax, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novavax, Inc.'s reported carbon emissions
Novavax, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. As such, there are no recorded emissions figures in kg CO2e, and no commitments to reduce emissions have been documented. The company does not inherit emissions data from a parent organisation, indicating that its climate commitments and performance are independently reported. Without specific data or targets, it is unclear how Novavax, Inc. is addressing climate change or its carbon footprint within the biopharmaceutical industry context. In summary, Novavax, Inc. has not disclosed any emissions data or reduction initiatives, leaving a gap in understanding its climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novavax, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
